comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 09:57:19 - browse：939

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Medical mystery: When a cough is not just a cough

knowledge

WSS

Beach reads and more: STAT's 2023 summer book list

It's time to get medical device identifiers over the finish line

California’s proposed $25 per hour health care minimum wage

Leqembi, other new Alzheimer’s drugs require better biomarkers

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Biogen Alzheimer’s drug launch off to slow start

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

knowledge

The high cost of giving birth even with insurance

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Medicare details structure of new drug price negotiation program

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Walensky prepares to leave CDC — and Congress — behind

PhRMA lawsuit over Medicare drug price negotiation tossed

Hollywood unions extend contract negotiations for actors

Biden report: The neurospychology of memory and aging

At least 13 dead in Texas as scorching temps continue

A new study sees potential in DNA sequencing of infants

focus

Readout LOUD podcast: How biotech is using artificial intelligence

Senators start work on Medicare physician payment reform

Oak trusses raised to roof of fire

How the political right came to back psychedelics to treat trauma

Why 40% Americans with Parkinson’s don’t see a neurologist

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

knowledge

hotspot

focus

focus